Study to evaluate release of glucose toxicity associated with SGLT2 inhibitors administered in patients with metabolic syndrome in type 2 diabetes

Study to evaluate release of glucose toxicity associated with SGLT2 inhibitors administered in patients with metabolic syndrome in type 2 diabetes - Study to evaluate release of glucose toxicity associated with SGLT2 inhibitors administered in patients with metabolic syndrome in type 2 diabetes

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000019660

Enrollment

Registered

2015-11-06

Start date

2015-11-01

Completion date

Unknown

Last updated

2025-07-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

SGLT2 inhibitors

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria:

Exclusion criteria

Exclusion criteria: (1)Patients with type 1 diabetes (2)Patients with a history of severe ketosis, diabetic coma, or diabetic pre-coma within 6 months prior to the start of study (3)Patients with severe infection or serious trauma, or in a pre- or post-operative phase (4)Patients with a history of hypersensitivity to the components of the study drug (5)Patients with severe renal dysfunction (eGFR <30 mL/min/1.73 m2) or end-stage renal failure undergoing dialysis (6)Patients with serious hepatic dysfunction (7)Pregnant or lactating women, or those expecting to become pregnant during the study period (8)Patients judged inadequate to enroll in the study at the discretion of principal investigator or subinvestigator

Design outcomes

Primary

Measure	Time frame
1.Blood glucose-related: HbA1c, fasting glucose, glucagon 2.Insulin secretion-related: fasting insulin, plasma glucose after glucose tolerance test, fasting blood CPR, CPI 3.Insulin resistance: Matsuda Index 4.Metabolic syndrome-related: Abdominal circumference, neutral fat, HDL cholesterol, blood pressure 5.Oxidative stress-related: high-sensitivity CRP, adiponectin	—

Countries

Japan

Contacts

Public ContactClinical

Bell Medical Solutions Inc. Clinical Research and Development

nakano.satomi@bell-medical.co.jp06-6920-7589

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Feb 4, 2026